BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $21

NeoGenomics, Inc. -2.41% Pre

NeoGenomics, Inc.

NEO

13.75

13.75

-2.41%

0.00% Pre

BTIG analyst Mark Massaro maintains NeoGenomics (NASDAQ: NEO) with a Buy and lowers the price target from $25 to $21.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via